Yuyang Gu

Dr. Yuyang Gu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YLYanjun Li
Yanjun Li
YZYefan Zhang
Yefan Zhang
QLQijun Li
Qijun Li
YGYuyang Gu
Yuyang Gu
YXYufen Xu
Yufen Xu
Hepatocellular carcinoma (HCC) is one of the most frequent diagnosed malignancies globally with dismalprognosis and high mortality. Transformer 2 beta homolog (TRA2B), known as serine/arginine-rich splicing factor 10 (SRSF10), is a member of the serine/arginine (SR) protein superfamily that modulates gene expression by regulating mRNA splicing. The significance of TRA2B in cancer has received considerable attention in recent years, however, its specific role and molecular mechanisms in HCC remain unknown. This study aimed to analyze the expression of TRA2B in LIHC with the support of integrative bioinformatic analysis. The study conducted Kaplan-Meier and cox regression analyses and showed that the upregulated TRA2B was notably correlated with the dismal prognosis in HCC. TRA2B was identified as a potential proto-oncogene in HCC associated with poor prognosis. TRA2B expression in tumor tissues was found to be elevated using bioinformatics analysis. Following that, non-coding RNAs (ncRNA) related to TRA2B were extracted using series analysis. The CRNDE/LINC00511-miR-29c-3p axis was characterized as a potential upstream ncRNA-correlated signaling of TRA2B in HCC. Subsequently, the role of TRA2B in the tumor immune microenvironment (TIME) was investigated. In summary, this research provides novel insight into the potential role of TRA2B across various cancers and indicated that ncRNA-mediated overexpression of TRA2B is associated with the dismal prognosis in HCC.

15 October 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
ZMZijuan Mao
Zijuan Mao
YGYuyang Gu
Yuyang Gu
GTGanxue Tao
Ganxue Tao
QDQiang Dai
Qiang Dai
YXYangjie Xu
Yangjie Xu
ZFZhenghua Fei
Zhenghua Fei
Purpose This study aimed to investigate the molecular links and mechanisms between Crohn’s disease (CD) and colorectal cancer (CRC). Methods This study used the Gene Expression Omnibus (GEO) database to identify Differentially expressed genes (DEGs) in CD (GSE112366) and CRC (GSE110224), analyzed by 'edgeR' and 'limma'. The Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes explored DEG functions, and the Search Tool for the Retrieval of Interacting Genes (STRING) informed the protein–protein interaction network construction visualized in Cytoscape (version 3.7.2). Cyto-Hubba identified key genes, whose biomarker potential for CD and CRC was evaluated. Results The study discovered 61 DEGs, with 44 up- and 17 down-regulated, linked to immune responses and signaling pathways. CXCL1, highly expressed in colon cancer, correlated with better prognosis and lower staging. It also showed associations with immune infiltration and checkpoint molecules, suggesting a role in cancer progression and retreat. Conclusion CXCL1 may play a role in the development of colorectal cancer from inflammatory bowel disease.

26 September 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YGYuyang Gu
Yuyang Gu
YLYanjun Li
Yanjun Li
TQTingting Qian
Tingting Qian
XXXiaofang Xu
Xiaofang Xu
Colon adenocarcinoma (COAD) ranks among the most prevalent malignancies. C-type lectin domain family 11 member A (CLEC11A) plays a role in the initiation and progression of various cancers. However, its involvement in COAD remains unclear. This study reveals that CLEC11A expression is significantly elevated in COAD tissues compared to normal counterparts. Moreover, higher CLEC11A levels correlate with advanced T and N stages as well as pathological stage. Survival analysis further indicates that elevated CLEC11A expression is linked to poor prognosis. Cox regression analysis identifies CLEC11A as an independent prognostic factor for unfavorable survival outcomes. Additionally, increased CLEC11A expression shows a positive association with immune cell infiltration and immune checkpoint markers. CLEC11A-related differentially expressed genes (DEGs) were also identified, and functional enrichment analyses were conducted to elucidate the biological roles of CLEC11A. Unsupervised cluster analysis of these DEGs across distinct subgroups was also performed. In conclusion, CLEC11A has the potential as both a prognostic biomarker and a modulator of immune responses in COAD.